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Purpose: To investigate the plausibility of clinically significant oxygen toxicity in 
patients with retinal disorders being treated with hyperoxia therapy. Supplemental 
oxygen therapy is a promising form of treatment that may help reduce ischemia and the 
subsequent symptoms in patients suffering from diabetic retinopathy (DR), retinal vein 
occlusions (RVOs), and age-related macular degeneration (AMD). Currently, few studies 
perform ongoing assessments of current hyperoxia trials in patient populations. By 
investigating a current cohort of patients using supplemental oxygen to mitigate 
symptoms in their ocular conditions, we hope to demonstrate the extremely low 
likelihood of oxygen toxicity in patients utilizing hyperoxia therapy. Through these 
results, we hope to demonstrate that supplemental oxygen therapy is a viable, safe 
method of treatment for patients with ocular disorders.  
Methods: A cohort of 16 patients was analyzed for changes in their C Reactive Protein 
(CRP), white blood cell count (WBC), hematocrit (Hct), and hemoglobin (Hb) levels 
after continuous use of hyperoxia therapy as part of treatment for varying retinal 
disorders. All study patients were diagnosed and under treatment at Beth Israel 
Deaconess Medical Center in Boston, MA. Patients diagnosed with diabetic retinopathy, 
retinal vein occlusions, or age-related macular degeneration were included in the study. 
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Each of these patients must have also been prescribed 5 L/min of nocturnal hyperoxia 
therapy. Patients with insufficient data either before or after beginning the hyperoxia 
therapy were excluded. Primary outcome variables were arranged as pre- and post- 
hyperoxia therapy data points for CRP, WBC, Hb, and Hct. P-values below 0.05 would 
indicate statistically significant risk of oxygen toxicity in these variables under the 
current hyperoxia treatment.  
Results: The mean age of the sample population was 64, with 6 of the 16 patients 
diagnosed with diabetes (37.5%). Patient groups were divided into diabetic vs. non-
diabetic to assess whether or not one group was affected differently by the hyperoxia 
therapy. Results showed p-values well over 0.05 for both groups, indicating that oxygen 
toxicity is not a major risk factor when using supplemental oxygen under the study’s 
conditions.  
Conclusion: A large number of patients with diabetes suffer from retinal problems, 
especially with the onset of old age. These problems eventually require treatment via eye 
injections, laser, and even surgery in order to preserve vision and mitigate edema and 
ischemia. Given the high cost and invasive nature of these procedures, hyperoxia therapy 
provides a safe and potentially beneficial alternative to mitigate the symptoms of these 
disorders. This study hoped to demonstrate the plausibility of widespread clinical 
application for supplemental oxygen therapy in retina patients, while concluding that 
oxygen toxicity is not a significant risk factor in this type of treatment. The outcomes of 
this study support this hypothesis, and lay the groundwork for future studies that may 
assess the risks of oxygen toxicity on a larger scale. More research is required to gauge 
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the true risks of oxygen toxicity in patients using supplemental oxygen. A case-controlled 
longitudinal study would also prove useful in providing data on changes in visual acuity 
and other experimental factors of interest, while accounting for several limitations present 
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Since the first biological organisms began to develop on planet Earth, 
continuously rising and fluctuating oxygen levels have dictated the evolution of complex 
life forms. These surging levels of atmospheric oxygen have correlated strongly with 
greater diversity in developing organisms, along with notable increases in individual 
complexity. 540 million years ago, these oxygen levels stabilized and, to the present day, 
have fluctuated at the habitable range of 15-35% oxygen concentration (Brugniaux et al. 
2018). Eventually, with the advent of humanity inspired an everlasting desire to question 
and define every aspect of the universe. The air in the atmosphere, including oxygen, and 
respiration was no exception and, in fact, served as a primary focus of inquisition. Early 
philosophers and scientists, such as Galen, quickly deduced the critical importance of 
respiration along with the flow of air through the human body being critical to the 
support of life (Fitting, 2015). The 18th century, however, became the most important 
time period for the description of oxygen.   
 In the early 18th century, a theory of the combustion of air – the phlogiston theory 
– was widely accepted. The theory posited that a substance similar to fire named 
“phlogiston” was released in respiration and combustion reactions (Britannica, 2019). 
Problems with this theory arose as experiments demonstrated that many metals gained 
mass when burned (oxidized). How could phlogiston be released from these metals and 
then gain mass? Prominent chemists of the time sought to disprove this theory, and in the 
mid 18th century, Henry Cavendish and Joseph Priestley established that burning 
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inflammable air yielded a pure water condensate (Fitting, 2015). Along with French 
chemist Antoine Lavoisier, they were able to prove that oxygen is an element at the heart 
of combustion, respiration, and calcination reactions – essentially, combustion requires a 
gas that has mass; in this case, oxygen (Britannica, 2019). With the isolation and 
identification of oxygen, its properties were then able to be more fully analyzed. 
 While it has long since been evident that oxygen is vital to the survival of all 
species dependent on respiration, higher-than-normal physiological levels of oxygen have 
also recently been used as a standard protocol in treating life-threatening medical 
emergencies (Helmerhorst et al., 2015). Depending on the circumstance, supplemental 
oxygen is administered in different ways. One common method is by administering a 
breathing mask or nasal cannula to a patient, where the air delivered is composed of an 
increased fraction of inspired oxygen (FiO2) (Hafner et al., 2015). By using an oxygen 
tank or concentrator, medical professionals and researchers can control the amount of 
inspired oxygen, ranging from the ambient amount of 21% to 100% oxygen. Under these 
conditions, the elevated fraction of inspired oxygen is administered at a normal air 
pressure of 1 atm and is thus referred to as a normobaric treatment. Certain medical 
conditions may require a greater amount of oxygen reaching the tissues, in which case 
hyperbaric oxygen therapy is implemented. Hyperbaric oxygen therapy exposes the 
patient to 100% oxygen at two to three atmospheres of air pressure, which is 2-3 times 
greater than the air pressure at sea level (Tibbles & Edelsberg, 1996). With this level of 
oxygen exposure, the patient’s dissolved oxygen content rises to levels sufficient to meet 
the resting cell physiological requirements without needing to rely on oxygen extracted 
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from hemoglobin (Tibbles & Edelsberg, 1996). These changes in oxygen levels can be 
seen below in Figure 1. Comparatively, normobaric hyperoxia would only raise the 
dissolved oxygen content in the blood to 25% of the amount that hyperbaric treatments 
would supply (Tibbles & Edelsberg, 1996). As a result, the rate and effectiveness of a 
normobaric treatment would decrease in comparison.   
 
Figure 1. Changing Oxygen Levels Over Time. At greater partial pressures of oxygen (PaO2) 
and greater arterial O2-Hemoglobin saturation levels (SaO2), total blood oxygen concentration 
reaches a maximum. Under hyperbaric conditions, dissolved blood oxygen levels increase (seen 
by dashed line) (Brugniaux et al., 2018).  
However, the use of oxygen under these circumstances has raised concerns for 
central nervous system toxicity and other systemic pathologies. Furthermore, the more 
recent use of supplemental oxygen by healthy patients, especially athletes, has brought 
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about concerns for negative side effects under these normal, healthy conditions 
(Brugniaux et al., 2018).  
French physiologist Paul Bert was one of the first scientists to describe oxygen 
toxicity when he showed its negative effects on insects, arachnids, and other organisms 
(Glasser, 1944). Later at the end of the 19th century, Joseph Lorrain Smith observed 
pulmonary irritation in test mice that were exposed to increasing barometric pressures of 
oxygen (Smith, 1899). It was later discovered that the basis for oxygen toxicity comes 
from the free radical byproducts of oxygen metabolism (Brugniaux et al., 2018). 
Incompletely reduced electrons along the electron transport chain form superoxide, which 
at greater amounts can cause damage to cells and DNA (Hafner et al., 2015).  
Over the ensuing century, hyperoxia became more understood, and its uses 
became more defined – medical professionals regularly implement its use in sick patients, 
while even healthy athletes have recently explored its effects in improving performance. 
With the increasing use of supplemental oxygen in various capacities, researchers have 
been studying the potential risk factors and negative side effects that accompany these 
treatments in different types of patients, illnesses, and circumstances. 
 
Neonates 
 Oxygen therapy is a common form of treatment for premature neonates, 
especially for those who suffer from pulmonary hypertension or respiratory distress 
syndrome. Pulmonary hypertension in neonates manifests from the infant’s inability to 
naturally complete its cardiopulmonary transition at birth (Costa et al., 2018). As a result, 
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the neonate’s tissues cannot receive sufficient oxygen, and immediate treatment is 
necessary. Many premature neonates also commonly suffer from bronchopulmonary 
dysplasia as a result of respiratory distress syndrome, in which their lungs’ alveoli are not 
sufficiently developed to provide enough oxygen to the body (Wang & Dong, 2018). A 
neonate suffering from pulmonary distress will be treated immediately with positive 
airway pressure treatment to prevent the airways from collapsing, as well as greater 
oxygen concentrations (Wang & Dong, 2018). As part of a more comprehensive 
treatment plan for respiratory distress syndrome or pulmonary hypertension, hyperoxia 
allows for proper development of the lungs and respiratory tract.  
Premature infants will have a lower antioxidant production capacity due to the 
lack of fully mature type II alveolar cells, the most important antioxidant mediators in the 
lungs. Consequently, the first few exposures to ambient air as well as hyperoxia 
treatments can damage the neonates’ lungs via oxidative stress (Wang & Dong, 2018). 
Under both conditions, administering oxygen at greater pressures and concentrations is 
common practice. Despite the necessity of supplemental oxygen under these pathologies, 
clinicians have noted varying negative side effects from these treatments, most notably 
oxidative stress (Wang & Dong, 2018). The oxidative stress results directly from a 
greater amount of reactive oxygen species (ROS), as the deficit in antioxidant production 
does not allow for them to be neutralized. Along with increased reactive oxygen species, 
oxidative stress from hyperoxia also increases inflammatory markers, which can 
contribute to developmental problems in the lungs (Wang & Dong, 2018). Research 
supports these side effects of oxygen therapy, as pulmonary artery smooth muscle cells 
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treated in vitro with hyperoxia for extended periods of time showed significant increases 
in inflammatory markers compared to the control group (Costa et al., 2018). Overall, 
neonates subject to this cellular damage often suffer from persistent lung problems for the 
rest of their lives. Several downstream consequences of hyperoxia exposure are displayed 
below in Figure 2. 
 
Figure 2. The effects of oxidative stress leading to bronchopulmonary dysplasia. Prolonged 
exposure to hyperoxia causes the production of ROS, inflammatory markers, and other cytokines, 
which can then lead to the development of bronchopulmonary dysplasia (Wang & Dong, 2018). 
 
While oxygen toxicity in neonates is a real issue, its negative side effects on adults are 
much less common, and are usually only seen under specific or extreme instances of 





Scuba Divers and Decompression Sickness 
 Oxygen toxicity in adults does not commonly occur unless under extreme or 
controlled conditions; however, the use of hyperoxia in hyperbaric chambers has shown 
to carry some risks. Decompression sickness is a condition that manifests as a result of 
dissolved nitrogen exiting the tissues after going from high to low pressures in a short 
amount of time (Gutvik et al., 2010). These air bubbles can restrict blood flow and cause 
many symptoms varying from dizziness to joint pain (Gutvik et al., 2010). 
Decompression sickness if untreated can lead to death. This most commonly occurs with 
divers that resurface too quickly after a deep dive. When placed in a hyperbaric chamber, 
the patient waits for several hours for the excess gas to leave the body without causing 
harm (Heyboer et al., 2017). While being a very safe and crucial form of treatment, 
hyperbaric chambers do carry risks of oxygen toxicity.  
One such risk is an arterial gas embolism if the highly pressurized air enters 
ruptured pulmonary vessels – a grave potential negative side effect (Heyboer et al., 
2017). Furthermore, there exists some risk for barotrauma to the ears and lungs if the 
patient is suffering from chronic obstructive pulmonary disease (COPD) or some 
condition with uncontrolled bronchopulmonary muscle spasms. These conditions could 
create a greater pressure gradient in the lungs, causing rupture or irritation to the tissues 
(Heyboer et al., 2017). In terms of oxygen toxicity, central nervous system (CNS) 
toxicity may occasionally occur if the patients’ antioxidant levels are not sufficient to 
counteract the greater amount of oxidative stress present during administration of 100% 
oxygen. CNS toxicity presents itself at first with muscle spasms and twitches, followed 
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later by seizures if the supplemental oxygen is not stopped (Chawla & Lavania, 2001). 
While very rare under these controlled conditions, it has been difficult to predict on an 
individual basis (Heyboer et al., 2017). Furthermore, prolonged exposure to greater 
oxygen percentages carries risk of pulmonary toxicity. If affected, a patient will suffer 
from irritation and edema of the alveolar tissue, as well as increasing destruction of the 
respiratory epithelium (Heyboer et al., 2017). Another major risk site for oxygen toxicity 
during hyperoxia is the eye – the most applicable area of interest for this study. The eye 
normally produces larger concentrations of reactive oxygen species that are removed by 
antioxidant defense mechanisms, including superoxide mutase (Heyboer et al., 2017). 
Under prolonged periods of hyperoxic exposure, these defense mechanisms may become 
overwhelmed, resulting in toxicity of the eye, including development of cataracts or 
myopic progression. However, these instances seldomly arise, with only one recorded 
instance of cataract development in a patient receiving less than 50 hyperoxia treatments 
(Heyboer et al., 2017). Overall, hyperoxia treatment, and in this case hyperbaric oxygen 




 A more recent utilization of supplemental oxygen therapy has been its use by 
athletes to boost their physical performance capacities. These practices have been 
controversial, as the World Anti-Doping Agency has not been regulating these practices 
(Brugniaux et al., 2018). Training at high altitudes (hypoxic conditions) is an already 
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established method of increasing an athlete’s hematocrit (Haile et al., 2018). Athletes also 
regularly practice high intensity interval training (HIIT) in attempts to increase their 
maximal oxygen uptake during intense exercise (VO2 max) (Menz et al., 2015). 
However, the effectiveness of hyperoxia therapy is not fully understood due to lack of 
consistent evidence of its positive impact on athlete performance. While an increasing 
number of athletes begin to apply supplemental oxygen into their training, researchers 
have attempted to identify physiological factors that may be improved from this 
treatment.  
 Various studies have been performed on athletes breathing greater fractions of 
inspired oxygen while exercising in order to measure their VO2 max. Training while 
breathing greater percentages of oxygen has shown reduced arterial hypoxemia in trained 
runners during heavy exercise (Astorino & Robergs, 2003). Furthermore, breathing 
supplemental oxygen during exercise has shown greater oxygen delivery to the tissues, 




Figure 3. Changes in VO2 max with increasing O2 delivery. VO2 max measurements were 
made on a cohort of rowers under both normoxia and 30% oxygen (hyperoxia). Results show a 
statistically significant increase in VO2 max under these conditions (Astorino & Robergs, 2003). 
 
While many researchers have found a general increase in VO2 max under 
hyperoxia, as seen in Figure 3, many of these results remain statistically inconclusive on 
a large scale, because different studies utilized varying fractions of inspired oxygen under 
different pressures, times, and other factors (Brugniaux et al., 2018). In terms of oxygen 
toxicity, many of these studies noted increases in vascular resistance and arterial blood 
oxygen concentration; however, the more serious potential negative side effects, such as 
CNS and pulmonary toxicity have not been prominent (Brugniaux et al., 2018). Further 
studies with more controlled parameters are necessary to not only study the effectiveness 
of hyperoxia on athletic performance, but to also gauge viable risks from greater amounts 
of oxygen exposure.  
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Patients with Life-Threatening Conditions 
 As previously discussed, supplemental oxygen treatment is part of standard 
protocols when treating patients with life-threatening conditions, as it provides the tissues 
with the oxygen distribution that may otherwise be impeded. During shock resuscitation, 
for instance, patients are placed under high fractions of inspired oxygen, most often 
100% (Hafner et al., 2015). There is sufficient evidence to prove that oxygen therapy 
brings about positive effects in shock patients, as seen below in Figure 4. However, the 
persistence of hyperoxia for prolonged periods of time has also been seen to bring about 
toxicity and even mortality in some patients (Hafner et al., 2015). When the fraction of 
inspired oxygen is raised to 100%, experimental animal studies have shown inflammation 
due to ROS and other cytokines to induce pulmonary edema and irritation (Hafner et al., 
2015). Other potential side effects include decreased cardiac output and vasoconstriction 




Figure 4. Various biochemical effects from breathing 100% oxygen. The green arrows show 
the benefits of hyperoxia, while the red show negative effects of hyperoxia during life-threatening 
conditions. PO2 = oxygen partial pressure, SO2 = oxygen saturation, DO2 = systemic oxygen 
transport, HPV = hypoxic pulmonary vasoconstriction (Hafner et al., 2015). 
 
While experimental animal trials have shown these potential negative side effects, 
there have not been consistent results in human patients to warrant the gravity of oxygen 
toxicity in patients suffering from critical conditions (Hafner et al., 2015). In order to 
obtain consistent data and form a viable conclusion, the need for a large scale trial is 
necessary. Despite the inconsistent results on humans at this current time, the risk factors 
for oxygen toxicity from hyperoxia in critically ill patients should not be discounted, 
especially those caused by reactive oxygen species.  
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Oxygen Toxicity and Cancer 
 The benefits of supplemental oxygen therapy are also harnessed for use in patients 
suffering from certain types of breast and lung cancer. As seen in Figure 4, the 
administration of hyperoxia in moderation can moderately decrease inflammation in the 
body and increase host defense systems by increasing cell efficiency (Hafner et al., 
2015). In cancer patients, metastasis of tumors to other parts of the body is indicative of a 
worse prognosis and increased progression of the cancer itself. In particular, the hypoxic 
tumor microenvironment is critical to the progression of tumor cells and their 
morphological changes that promote their motility and invasion of distant sites in the 
body (Yttersian et al., 2017). This hypoxic environment will limit the hypoxic inducible 
factor 1 (HIF-1), which regularly shuts off genes that are otherwise promoted by the 
hypoxic tumor microenvironment (Yttersian et al., 2017).  
Researchers have proposed that hyperoxia therapy could aid in mitigating tumor 
growth by suppressing the hypoxic tumor microenvironment. Yttersian et al. investigated 
these effects by subjecting a group of mice with breast cancer to hyperbaric oxygen 
therapy every three days during a 54 day treatment period. Results seen below in Figure 5 




Figure 5. Observed metastases after hyperbaric oxygen therapy. Experimental group shows 
decreased number and area of metastases compared to control group. Histological section 
demonstrates the same outcome (Yttersian et al., 2017) 
 
A similar study performed on mice given 60% normobaric oxygen also provides 
support for this conclusion, as this experimental group showed decreased 
immunosuppression as a result of the oxygen therapy (Hatfield et al., 2015). 
Consequently, the increase of otherwise suppressed T and Natural Killer (NK) cell 
activity was restored, allowing for the mitigation of tumor growth (Hatfield et al., 2015). 
Apart from mitigating the hypoxic aspect of the tumor microenvironment and promoting 
the T and NK cell immunoresponse, the mechanism behind hyperoxia use in cancer cells 
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involves increased ROS and cell cycle arrest (Kim et al., 2018). Despite the potential 
benefits of hyperoxia working in tandem with classical cancer treatments, there do exist 
the risks of the negative side effects of oxygen toxicity (Waris & Ahsan, 2006).  
As previously discussed, reactive oxygen species carry the potential to cause cell 
damage. Additionally, the excess production of ROS combined with an imbalance in 
antioxidant levels can initiate the progression of cancer (Waris & Ahsan, 2006). It has 
also been shown in animal studies and certain human patients that excess exposure to 
hyperoxia has induced toxicity to the lungs and central nervous system. Therefore, with 
these risks in mind, medical professionals must be cognizant of the potential side effects 
that hyperoxia could add to the progression of cancer in their patients. Along with 
causing changes in DNA leading to cancer progression, oxygen toxicity has also been 
correlated to diabetes and neurodegenerative disorders (Waris & Ahsan, 2006). In 
diseases such as diabetes, their progression has been associated with increased 
mitochondrial ROS in the muscle and impaired glucose clearance (Waris & Ahsan, 
2006). While it is rare for oxygen toxicity to reach a critical stage in patients, it is 
important to note these risk factors when administering hyperoxia to cancer patients.  
 
How Oxygen Toxicity Affects Individual Body Systems 
 Currently, the effects of supplemental oxygen and oxygen toxicity have been 
discussed on a general scale in patients in specific medical scenarios or in those suffering 
from various illnesses or diseases. This section will delve deeper into which particular 
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organ systems may be affected by oxygen toxicity and how this toxicity may impact their 
normal function.  
 Central nervous system (CNS) toxicity, as previously mentioned, is one common 
form of oxygen toxicity that can occur under exposures to high partial pressures of 
oxygen (Brugniaux et al., 2018). Preliminary symptoms include dizziness, nausea, and 
confusion, followed by seizures under prolonged exposure. These symptoms are 
reversible once the partial pressure of oxygen is reduced (Brugniaux et al., 2018). CNS 
toxicity is most commonly seen in divers or patients undergoing hyperbaric oxygen 
therapy, whereas prolonged exposure to normobaric oxygen therapy carries more risk for 
toxicity in the lungs or eyes (Brugniaux et al., 2018). Symptoms of pulmonary toxicity in 
healthy patients have been seen to arise after exposure to normobaric 100% oxygen 
lasting longer than 10 hours (Chawla & Lavania, 2001). Once exposure of 100% oxygen 
exceeds 24 hours, irritation of the respiratory tract is observed, and increases significantly 
after 48 hours. Pulmonary toxicity is most serious when hyperoxia is administered under 
hyperbaric conditions, with dyspnea and chest pains being the most significant (Chawla 
& Lavania, 2001). Pulmonary toxicity is also applicable in the case of patients suffering 
from COPD. While oxygen therapy is a proven method of improving tissue oxygenation 
in COPD patients, there still exists the risk of toxicity and carbon dioxide (CO2) narcosis 
(Brugniaux et al., 2018). Contrary to healthy patients, those with COPD are prone to CO2 
retention, which may be propagated by prolonged hyperoxia therapy. In turn, this could 
result in carbon dioxide narcosis, which can lead to respiratory acidosis and coma 
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(Brugniaux et al., 2018). As a result, it is clinically important to monitor the oxygen and 
carbon dioxide partial pressures in patients with COPD (Fraser et al., 2016).  
 The cardiovascular system is another area of importance regarding oxygen 
toxicity, as there have been various studies that have yet to draw consistent conclusions 
regarding the effects of hyperoxia. The potential influence of supplemental oxygen on 
hemoglobin (Hb) levels is one primary point of interest that may have clinical 
significance. Studies performed on athletes training at different altitudes assessed their 
hemoglobin levels before and after the training period. In one study involving an 
experimental group undergoing high intensity interval training, no significant changes in 
hemoglobin levels were observed compared to the control group (Menz et al., 2015). A 
separate study observed changing Hb levels in an experimental group injected with 
recombinant erythropoietin – this group of athletes showed increased Hb levels in those 
training at sea level vs. at altitude (Haile et al., 2018). Ultimately, this last study showed 
that athletes not normally lacking in hemoglobin increase production most likely due to 
the introduction of erythropoietin (EPO) into their systems. The impact of varying levels 
of FiO2 is ultimately not clear; however, the breathing of pure oxygen is more clinically 
significant in patients that have a lower hemoglobin concentration (Hafner et al., 2015). 
With a lower Hb concentration, hyperoxia would assist in meeting the total blood O2 
demands of the body.  
 Another important risk factor in hyperoxia is the potential change in blood 
pressure and vascular tone. While significant changes in overall blood flow have not been 
consistently observed, hyperoxia has been shown to cause vasoconstriction and thus 
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decreases in cardiac output (Brugniaux et al., 2018). In a separate study, Siński et al. 
subjected 19 subjects to 100% oxygen for 15 minutes and noted no significant change in 
central aortic blood pressure, while peripheral pressure showed varying changes (2016). 
In terms of blood pH, acid/base blood levels have been similar during both normoxia and 
hyperoxia (Astorino & Robergs, 2003).  
 The effects of hyperoxia and oxygen toxicity become most applicable to this 
study in relation to the eye, as the potential side effects could influence the course of 
treatment in pre-existing conditions. Oxygen toxicity is often associated with an 
imbalance in reactive oxygen species. As a result of hyperbaric oxygen therapy, seven of 
fifteen patients in one study were seen to develop nuclear cataracts (Palmquist et al., 
1984). These patients were receiving oxygen therapy for reasons unrelated to the eye, yet 
these side effects were noted. The increased ROS and sensitivity of the crystalline lens 
are the reasons for this development; however, when a different group was subjected to 
lesser amounts of hyperbaric oxygen therapy, cataracts did not form (McMonnies, 2015). 
Similarly, nuclear cataracts commonly form after vitrectomy surgeries, most likely due to 
the exposure of the posterior portion of the lens to increased oxygen levels (Holekamp et 
al., 2005). Figure 6 displays observed changes of oxygen levels in the eye before and 
after a vitrectomy. In both cases, it is apparent that managing appropriate oxygen partial 




Figure 6. Oxygen tension in the eye prior and post-vitrectomy. The measurement of oxygen 
tension in patients’ (n=18) vitreous bodies before and immediately after vitrectomies. Results 
show that oxygen tension post-vitrectomy was significantly higher both adjacent to the lens and 
in the center of the vitreous (Holekamp et al., 2005). 
  
The negative effects of excessive amounts of reactive oxygen species may also 
accelerate the progression of other diseases, such as age-related macular degeneration 
(AMD). Oxidative stress causes the damage of the retinal pigment epithelium, especially 
in older patients; and with longer exposures to hyperoxia, there is an increased risk of 




The use of oxygen has been shown to have potential benefits for several ocular 
diagnoses, including retinal detachment. Upon retinal detachment, the photoreceptor 
region becomes ischemic and leads to rapid photoreceptor degeneration (Arroyo, 2018). 
The ischemic factor in photoreceptor degeneration becomes the most significant aspect of 
potential treatment in this study. Upon detachment, the retina needs to be reattached 
either surgically or by some other procedure. Usually, the patient must wait a certain 
period of time before this procedure can take place, which permits the retinal 
photoreceptors to degenerate and damage further (Mervin et al., 1999). As a result, 
supplemental oxygen therapies have been proposed as potential treatments for the 
preservation of retinal photoreceptors.  In a 1999 study, Mervin et al. induced retinal 
detachment in a group of cats, after which they studied the effects of hyperoxia on the 
experimental group left in a hyperbaric chamber vs. a control group that was left to 
recover at normal atmospheric oxygen levels. Retinal examination showed that three days 
of hyperoxia post-detachment greatly reduced photoreceptor death. 
With clinical benefits also seen in reducing inflammation in patients with AMD 
and macular edema, researchers must identify and keep track of certain parameters in 
order to manage the hyperoxia therapy and prevent toxicity. Most of the patients in this 
study were subjected to complete blood count (CBC) and visual acuity tests. As part of 
the complete blood count test, special attention was paid to the hemoglobin levels and C 
reactive protein (CRP), which is a direct indicator of inflammation in the body (Mayo 
Clinic, 2017). Using these parameters, alongside continuous evaluation of each patient’s 
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condition, their Hb and CRP levels are being used to see if prolonged use of supplemental 
oxygen will bring about negative physiological side effects. Other measures are being 
developed to gather a more standardized effectiveness of hyperoxia therapy in a group of 
patients being otherwise treated for recurrent eye conditions. Such measures include a 
standardized patient questionnaire that will assess pre and post-treatment factors, such as 
energy levels, comfort, etc.  
While the use of hyperoxia therapy in this group of patients is not expected to 
produce noticeable amounts of oxygen toxicity, it is important to explore ways to 
mitigate and even prevent this toxicity. It has been noted that the effects of oxygen 
toxicity are worsened when the patient has dietary deficiencies of selenium, zinc, and 
magnesium; thus, necessitating the management of healthy vitamin and mineral levels in 
the body (Chawla & Lavania, 2001). As increased ROS from the hyperoxia therapy pose 
greater risk to sensitive cells in the eye, patients would benefit from antioxidant vitamin 
supplements. It has been shown that people taking antioxidant vitamins are less likely to 
progress to late AMD – thus a mitigation of the negative effects of ROS (Evans & 
Lawrenson, 2017). Furthermore, by taking antioxidant supplements, patients may also 
help prevent oxygen toxicity from affecting their lungs, CNS, and other sensitive areas.  
This study takes a detailed look at a group of patients suffering from AMD, 
macular edema, and retinal vein occlusions in an attempt to gauge the effectiveness and 






 There are many ways in which supplemental oxygen is used both within and 
outside the medical profession. Occasionally, the overuse or overexposure to this 
supplemental oxygen at higher pressures or concentrations may elicit negative symptoms, 
or oxygen toxicity. This study seeks to define and investigate certain variables that may 
be affected by the use of hyperoxia therapy in a group of patients suffering from several 
eye disorders. Furthermore, this study seeks to determine whether or not oxygen toxicity 
is a significant risk factor in patient health when under hyperoxia therapy for extended 
periods of time. This study hypothesizes that supplemental oxygen therapy poses no 






Inclusion and Exclusion Criteria 
Having observed the benefits of supplemental oxygen therapy in retinal 
detachments, this same treatment plan was expanded to a larger sample of patients 
suffering from other eye pathologies. These include age-related macular degeneration, 
complications of diabetic retinopathy, and retinal vein occlusions. It is thought that 
supplemental oxygen can be used to reduce symptoms of macular edema in patients, 
especially those with diabetic retinopathy. All patients identified for this study were taken 
from one retinal surgeon treating them for varying severities of diabetic retinopathy and 
retinal vein occlusions. Some patients with AMD were also included; however, any 
patient with COPD was excluded. Every patient in this sample must have had a complete 
blood count and CRP measurement prior to and post hyperoxia therapy. A sample of 54 
patients were initially identified. Of this cohort, patients not being treated with hyperoxia 
therapy were excluded, as the purpose of this study was to measure the potential effects 
of oxygen toxicity in treatment patients. Oxygen patients without adequate follow-up data 
were also excluded from the study. The final sample used for statistical analyses 
comprised of 16 patients. 
 
Diagnostic Procedures 
 Prior to commitment of a full course of hyperoxia treatment, patients were 
subjected to a three-hour preliminary oxygen trial. The patients were prescribed the 
oxygen trial if their course of treatment showed potential benefits from the hyperoxia 
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therapy. Patients were seen in the Beth Israel Deaconess Medical Center Department of 
Ophthalmology for a full assessment prior to deciding on a complete hyperoxia 
treatment. In the clinic, patients first underwent an ETDRS (Early Treatment Diabetic 
Retinopathy Study) visual acuity and contrast sensitivity exam. Eye pressure and an 
optical coherence tomography (OCT) scan were also taken prior to beginning the oxygen 
trial. These measurements were used as the reference for the post-oxygen trial exams. 
Afterwards, the patients were placed in a seating area and administered 5 Liters per 
minute of oxygen via a non-rebreathing mask supplied by an oxygen tank or oxygen 
concentrator. After three hours of continuous exposure to the supplemental oxygen, the 
patient was reassessed with another visual acuity exam, contrast sensitivity test, and eye 
pressure was taken. A second OCT scan was taken with the pre-oxygen trial scan used as 
the reference point. Following this second round of tests, a complete ophthalmoscope 
exam was performed in both eyes to explore the posterior pole of the eye in search of any 
novel abnormalities. At this point, the changes in retinal thickness seen in the OCT scan 
were analyzed, and if a significant change was noted as a result of the three-hour trial, 
continuous use of the hyperoxia therapy was prescribed. Figure 7 summarizes the study 




Figure 7. Study Design Flow Chart. This flow chart depicts the procedures taken when carrying 
out this study. The chart also indicates the time points at which data was collected prior to 






Full-Length Hyperoxia Treatment 
In the clinic these patients regularly undergo several courses of treatment to 
manage edema and preserve central vision. These include pan retinal photocoagulation, 
argon laser, and laser barrier treatments, as well as regular injections of Avastin 
(bevacizumab) or Eylea (aflibercept). The injections help reduce the swelling and 
neovascularization that results from disease-related ischemia. The use of hyperoxia is an 
attempt to reduce the number of injections and other invasive treatments, while also 
preserving vision and oxygen perfusion in the tissues.   
The full hyperoxia therapy was carried out by the patient in their home using a 
continuous positive airway pressure (CPAP) machine. The patient was prescribed to use 
oxygen at 5 Liters per minute for any amount of time that they could accommodate into 
their daily schedules. These times were self-recorded and varied from 3 hours per day to 
about 8 if the patient used the machine while sleeping. Physiological changes or effects 
seen from this continuous use of hyperoxia treatment were analyzed at a follow-up 
consultation, where ETDRS vision, contrast sensitivity, intraocular pressure, and an OCT 
scan were taken. 
 
Visual Acuity and Contrast Sensitivity Measurements 
A visual acuity test checks to see how well the patient can see letters or symbols 
from a given distance. The specific visual acuity test employed in this study was the 
Early Treatment Diabetic Retinopathy Study (ETDRS) vision test. This test was designed 
to more accurately measure visual acuity by reducing the imprecisions seen in the 
	
27 
standard Snellen test (Shamir et al., 2016). The ETDRS vision board includes an equal 
number of letters per row with equal spacing of the rows of letters (Shamir et al., 2016). 
The test board used in this study is capable of measuring 20/200 vision at a distance of 13 
feet (Vector Vision). Each sampled patient was administered the ETDRS vision test 
under the same conditions. Every patient was tested with the same distance of thirteen 
feet and with the same illumination, that being solely the background light from the 
ETDRS board itself.  
Alternatively, the contrast sensitivity exam tests how well a patient can 
distinguish between differing changes of light versus dark (MacuHealth). The contrast 
sensitivity board allows patients to receive the test under the same conditions, at a 
distance of 8 feet with the background board light being the only light source for the 
examination. The board contains four separate lines of eight pairs of circles. Each pair of 
circles is labeled with numbers 1 through 8, and the patient must choose which of each 
pair contains the marked lines. Measurements were taken on a standardized patient sheet, 
with the final correct identification in each line being marked for each of the four total 
lines. Below in Figure 8, the CSV-1000E Standardized Contrast Sensitivity Test is 
displayed. This is one of the most common contrast sensitivity tests used at present day, 




Figure 8. CSV-1000E Contrast Sensitivity Test. Four rows of sine wave gratings are presented, 
each testing the patient's ability to distinguish between light and dark. The readings are marked 
and used to interpret the patient's level of vision in regards to contrast sensitivity (Vector Vision). 
 
Measurements of Oxygen Toxicity 
Having taken the above detailed measures in each oxygen patient, it was 
concluded that there is potential risk for oxygen toxicity in these patients undergoing 
hyperoxia therapy. Patients’ complete blood count and C Reactive Protein (CRP) levels 
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were collected prior to the start of their hyperoxia therapy. The same measures were 
recorded over the course of the oxygen treatment at three month intervals, although some 
patients received their complete blood counts at time points earlier or after the three-
month interval. Any potential changes were noted and analyzed. Specifically, a complete 
blood count measured several components in the blood, including hemoglobin (Hb), 
hematocrit, and white blood cell numbers. These individual readings were considered 
when analyzing whether or not the hyperoxia therapy had any potential negative side 
effects on the sample patients.  
 
Statistical Analysis 
 Statistical analysis was completed using Microsoft Excel 2017. Logistic analysis 
compared pre-oxygen therapy parameters to the 3-month oxygen trial data for significant 
changes. Parametric analysis involved a Welch two sample t-test. The p-value was 
considered significant at the 0.05 level, or 95% confidence interval. 
 The points of interest in this statistical analysis were the outcome variables. In this 
study three main variables were collected from the patients’ complete blood counts and 
lab tests and analyzed to determine the potential for oxygen toxicity in their hyperoxia 
treatments. Significant changes in C Reactive Protein denoted potential of oxygen 
toxicity due to its direct correlation to inflammatory factors in the body. Hemoglobin and 
hematocrit levels were measured both pre and post oxygen therapy to determine if 
oxygen carrying capacity was compromised or influenced over the course of the 
treatment. Changes in white blood cell count were also assessed. The control used in this 
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study is the well-established assumption that patients with healthy respiratory function 
are not normally at any risk of oxygen toxicity when not being administered any 
supplemental oxygen, as toxicity arises from prolonged exposure usually under greater 
pressures (Chawla & Lavania, 2001; Brugniaux et al., 2018). Furthermore, these risk 
factors present themselves in those patients exposed to hyperoxia treatment at greater 
fractions of inspired oxygen over the course of their disease. The data sampled from these 
experimental patients was thus analyzed. Statistical analysis was performed for a within 
group test on the changes in C Reactive Protein, hemoglobin, hematocrit, and white blood 






Pre Treatment Data 
 A total of 16 patients were included in this study, as they matched the necessary 
inclusion criteria. The pre-oxygen therapy patient characteristics are displayed below in 
Table 1. The sample population is skewed female, with 13 males (81.25%) and 3 females 
(18.75%). The patients’ age ranged from 37 – 89 with a mean of 64.1. The 16 patients in 
this study were split into diabetic and non-diabetic groups, with 6 of the 16 (37.5%) total 
patients suffering from diabetes and its related complications. 4 patients were diagnosed 
with proliferative diabetic retinopathy (25%). Three patients had age-related macular 
degeneration (18.75%), and three patients had been diagnosed with a macular hole 
(18.75%). 2 of the 16 patients had a posterior vitreous detachment (12.5%). Another 2 of 
the 16 patients had suffered from a retinal detachment, and a further 2 had been treated 
for a central retinal vein occlusion (12.5%). 2 of the 16 sample patients were being 
treated for clinically significant macular edema (12.5%). Finally, one of the 16 patients 
was being treated for a branched retinal vein occlusion (6.25%), with another patient 







Table 1. Pre Oxygen Treatment Factors. Individual patient characteristics are shown, with the 
integers representing the number of patients in each category. The percent of the population are 
shown in parentheses. 
ALL PATIENTS (n=16)   
Sex Male 13 (81.25%) 
 Female 3 (18.75%) 
Age Mean 64.125 
 Median 65.5 
 Range 37 - 89  
Preliminary Condition Diabetes 6 (37.5%) 
 BRVO 1 (6.25%) 
 CRVO 2 (12.5%) 
 AMD 3 (18.75%) 
 MH 3 (18.75%) 
 PVD 2 (12.5%) 
 ERM 1 (6.25%) 
 RD 2 (12.5%) 
 CSME 2 (12.5%) 
 PDR 4 (25%) 
 
Diabetic Patient Group 
 A total of 6 patients comprised the diabetic patient group, where individual 
factors were separately identified and analyzed within this group. These factors can be 
seen in Table 2. The averages of the patient data for each factor were taken and recorded 
for both pre and post-hyperoxia therapy. The standard deviations are shown in 
parentheses for each reading.  
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All patients had been undergoing hyperoxia therapy, and the readings taken 
include before and after recordings to gauge potential influences by the hyperoxia therapy 
itself. Five of the six diabetic patients recorded C Reactive Protein readings prior to and 
after the start of their hyperoxia therapies. All six diabetic patients provided pre and post-
hyperoxia therapy data for their white blood cell count, hemoglobin, and hematocrit 
factors. The averages for each factor were also recorded, with the standard deviations 
shown in parentheses.  
 
Table 2. Diabetic Patient Group Data. Shown below are the factors of interest, with the number 
of patients in each group in parentheses. Averages for each group are recorded, with the standard 
deviations in parentheses next to each reading. 
DIABETICS (n=6)   
 Pre-O2 Trial Post-O2 Trial 
CRP (n=5) 3.32 (±3.18) 3.4 (±4.24) 
WBC (n=6) 8.22 (±3.82) 7.27 (±2.38) 
Hb (n=6) 12.8 (±0.57) 12 (±1.26) 
Hct (n=6) 39.1 (±2.32) 37.4 (±3.9) 
 
Non-Diabetic Patient Group 
 A total sample size of 10 non-diabetic patients were selected for the non-diabetic 
group. Of these patients, six were able to provide C Reactive Protein data. Nine of the ten 
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patients were able to provide recordings for their white blood cell, hemoglobin, and 
hematocrit count. Pre and post-hyperoxia therapy data was recorded for this group as 
well. The standard deviations for each reading were recorded in parentheses for each data 
point. The results from the non-diabetic group were measured to compare any potential 
changes in the four variables seen below in Table 3. The purpose of this before and after 
measurement was to determine any potential oxygen toxicity from the regular use of 
supplemental oxygen in these patients.  
 
Table 3. Non-Diabetic Patient Data. Shown below are the averages for each variable in a total 
non-diabetic sample group of n=10. Within this group, the variables CRP, WBC, Hb, and Hct 
were measured at different n values. Pre and post-oxygen therapy data was averaged and reported 
below. The standard deviations are placed in parentheses next to each recording.  
NON-DIABETICS (n=10)   
 Pre-O2 Trial Post-O2 Trial 
CRP (n=6) 17.1 (±23.6) 2.9 (±2.25) 
WBC (n=9) 6.1 (±0.95) 5.72 (±0.54) 
Hb (n=9) 14.1 (±0.95) 13.8 (±1.45) 







 A Welch two-sample t-test was conducted using the data points seen in Tables 2 
and 3. P-values were measured at the 0.05 level, or 95% confidence interval. Any value 
below 0.05 would be considered statistically significant. This statistical significance 
would thus indicate some potential negative side effect in that particular variable as a 
result of the hyperoxia therapy. P-values were calculated for C Reactive Protein, white 
blood cell count, hematocrit, and hemoglobin for both the diabetic and non-diabetic 
groups. P-values were also calculated for all patients combined for each variable. Below, 
Table 4 displays the p-values for the four test variables for the diabetic group, non-
diabetic group, and all patients. Every calculated p-value for each variable resulted above 











Table 4. P-values indicating potential oxygen toxicity. Shown are the p-values calculated in a 
Welch two sample t-test. Values below 0.05 are considered statistically significant and are 
bolded. The All Patients group shows the p-values calculated for both the diabetic and non-
diabetic groups combined.  
Pre vs. Post P Values    
 Diabetic Group 
Non-Diabetic 
Group All Patients 
CRP 0.974 0.207 0.205 
WBC 0.619 0.319 0.458 
Hb 0.209 0.612 0.325 
Hct 0.39 0.948 0.669 
 






 This study attempted to gauge the risks of developing significant oxygen toxicity 
from hyperoxia therapy from a carefully selected sample of patients. Patients already 
being treated for varying severities of different eye conditions were selected to undergo 
hyperoxia therapy to mitigate their symptoms. With pre- and post-therapy data points 
recorded, statistical analysis was conducted. 
 
On Results 
The results of the Welch two sample t-test fell under the expected range. 
Calculated p-values for C Reactive Protein, white blood cell count, hemoglobin, and 
hematocrit all fell comfortably over the 0.05 level, or 95% confidence interval. The p-
values ranged from 0.207 to 0.948 (Table 4). These values indicate that there is no 
statistically significant risk of oxygen toxicity in regards to these four variables. There 
was not enough sufficient change in these variables after the start of the hyperoxia 
therapy to conclude that clinically significant risk of oxygen toxicity would be plausible.  
These results were expected, as related current studies have yet to present 
consistent cases of oxygen toxicity in a given sample of study patients (Brugniaux et al., 
2018). Most cases of oxygen toxicity have occurred under extreme exposure to consistent 
levels of hyperoxia under both hyperbaric or normobaric conditions. The patients in this 
study were exposed to 5 L/min of normobaric oxygen for several hours each day, either 
during the daytime or at night during sleep. This level of exposure of supplemental 
oxygen rarely demonstrated negative side effects in patients lacking more serious 
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systemic conditions, as was the case with this sample population (Brugniaux et al., 2018). 
In addition to oxygen toxicity affecting a patient on a systemic level, it would be 
beneficial to observe oxygen perfusion at the ocular level. In disorders such as retinal 
vein occlusions or when retinal circulation is compromised as a result of diabetic 
retinopathy, a hypoxic environment is created in the retina. Future studies looking more 
closely into the effects of hyperoxia therapy on oxygen perfusion in the retina could 
prove useful in clinical practice (Wangsa-Wirawan & Linsenmeier, 2003). The viability 
of conducting such measurements in human patients could be made possible through the 
use of oxygen-sensitive microelectrodes (Linsenmeier & Zhang, 2017). The use of 
microelectrodes would allow for a non-invasive, yet accurate method of measuring 
oxygen concentration in the retina (Linsenmeier & Zhang, 2017). Consequently, this 
would permit future studies to assess the efficiency of hyperoxia therapy in preserving 
retinal blood and oxygen perfusion, as well as determining if oxygen toxicity is a 
significant risk factor under current treatment protocols.  
 Although this study did not indicate risk of oxygen toxicity through the 
experimental variables, more conclusive results may be drawn through future evaluation 
of carbon dioxide levels in the patients’ breathing masks. Given the relatively small risk 
of oxygen toxicity in normobaric hyperoxia therapy, the investigation of potential risks 
for carbon dioxide toxicity would prove clinically useful. Future related studies would 
measure carbon dioxide levels in the rebreathing masks used by hyperoxia therapy 
patients and compare these levels to similar variables assessed in this study. This would 
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prove particularly useful, as patients have clinically shown a wide range of tolerance to 
carbon dioxide levels (Permentier et al., 2017).  
  
Limitations 
 The results of this study were consistent with the proposed hypothesis – oxygen 
toxicity is not a significant risk factor in the sample of hyperoxia therapy patients being 
treated for a range of eye disorders. Despite these conclusions, several limitations exist in 
this study. The first of these limitations is the fact that this study was a small scale trial. 
All study patients were diagnosed and prescribed the hyperoxia therapy under the same 
clinical conditions, including a full fundus exam, visual acuity, and contrast sensitivity 
tests. Of the 54 available patients, only 16 of them met the inclusion criteria. The 
exclusion of the remaining patients came from a lack of sufficient data, something that 
could be compensated for in future studies by increased accountability by both 
researchers and patients when collecting the data. Ensuring regular three-month follow-
up consultations along with a full complete blood count would greatly improve the 
reliability of the results. A larger sample size in future studies would also provide more 
accurate conclusions in relation to a standard population size.  
 Another important limitation in this study is the reliability of the self-reported 
patient data. Apart from the preliminary three-hour trial conducted in the clinic at Beth 
Israel Deaconess Medical Center, all patients were responsible for using the supplemental 
oxygen on their own time each day. Furthermore, they were required to report all 
hyperoxia usage at each of their follow-up examinations over the course of their 
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hyperoxia treatment. The accuracy of the self-reported usage of the supplemental oxygen 
could have potentially altered the observed results in the p-value calculations. Future 
studies would attempt to implement a standardized method of keeping records of the 
patient use of the supplemental oxygen, one option being an automatic meter on the 
CPAP machine. A further limitation to consider is the presence of other health conditions 
that may have interfered with the patient’s ability to regulate oxygen perfusion and 
antioxidant levels in the body. As previously discussed, a compromise in the ratio of 
oxidant to antioxidant levels impedes the body’s ability to mitigate the negative 
consequences brought about by reactive oxygen species (Heyboer et al., 2017). As a 
result, more tissue damage may occur. Therefore, future studies would benefit from 
standardizing the study patients to certain disorders or identifying the full range of 
applicable conditions that may impact the course of hyperoxia therapy.  
 A final limitation of this trial involves the time frames in which each experimental 
variable was assessed. Most patients received complete blood count tests at some point 
prior to the start of their hyperoxia therapy and three months after the start of the 
supplemental oxygen use. However, some of these complete blood counts were 
performed months prior to the start of the oxygen trials. Additionally, some patients 
received complete blood counts less than or more than three months after beginning 
hyperoxia therapy. The varying time points of data collection may have potential impacts 






The goal of this study was to determine whether or not oxygen toxicity is a viable 
risk factor in a select sample of patients undergoing hyperoxia therapy. Given the test 
variables and patient population utilized in this study, it was concluded that oxygen 
toxicity is not a statistically significant risk to these patients. To generalize these 
conclusions to a larger population size, a full-scale longitudinal trial should be performed. 
This future study would have a larger patient population studying the same variables. 
Visual acuity changes and retinal oxygen perfusion should also be recorded in study 
patients for applicability in clinical practice. Overall, while there is room for future 
assessment of risks for oxygen toxicity in hyperoxia therapy, this form of treatment 
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